Panobinostat Synergistically Enhances the Cytotoxicity of Microtubule Destabilizing Drugs in Ovarian Cancer Cells

Area of Science:

• Oncology
• Pharmacology
• Cell Biology

Background:

• Ovarian cancer (OC) has a high mortality rate due to late diagnosis and chemotherapy resistance.
• Microtubule Destabilizing Agents (MDAs) are a promising class of compounds that inhibit OC cell proliferation.
• Novel therapeutic strategies are urgently needed to overcome treatment resistance in OC.

Purpose of the Study:

• To synthesize and characterize a novel microtubule-destabilizing agent, PILA9, for ovarian cancer treatment.
• To evaluate the efficacy of PILA9 alone and in combination with Panobinostat against OC.
• To elucidate the underlying mechanisms of synergistic cytotoxicity observed with the combination therapy.

Main Methods:

• Synthesis and characterization of the novel compound PILA9.
• Assessment of PILA9's effects on OC cell proliferation, cell cycle, and apoptosis.
• In vitro evaluation of the combination therapy using MDAs and Panobinostat.
• Analysis of α-tubulin acetylation levels.

Main Results:

• PILA9 demonstrated significant inhibition of OC cell proliferation, G2/M cell cycle arrest, and apoptosis.
• PILA9 exhibited greater cytotoxicity compared to previously described Microtubule Destabilizing Sulfonamides (MDS).
• Panobinostat synergistically enhanced the cytotoxicity of MDAs, including PILA9.
• The combination therapy led to increased α-tubulin acetylation, potentially explaining the observed synergy.

Conclusions:

• PILA9 is a potent novel microtubule-destabilizing agent with significant anti-cancer activity against ovarian cancer.
• The combination of MDAs with Panobinostat represents a promising synergistic therapeutic strategy for ovarian cancer.
• Targeting microtubule dynamics and histone deacetylase inhibition offers a novel approach for overcoming OC chemotherapy resistance.